9 results match your criteria: "Brown Universitygrid.40263.33[Affiliation]"
Antimicrob Agents Chemother
October 2022
Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA.
The standard of care for serious Enterococcus faecalis infections is ampicillin plus ceftriaxone. Ampicillin's inconvenient dosing schedule, drug instability, allergy potential, along with ceftriaxone's high risk for Clostridioides difficile infection and its promotion of vancomycin-resistant enterococci (VRE), led our team to explore alternative options. This work aimed to understand the role of carbapenems in combination with cephalosporins in these infections.
View Article and Find Full Text PDFAntimicrob Agents Chemother
October 2022
Department of Medicine, University of California, San Franciscogrid.266102.1, California, USA.
The proteasome is a promising target for antimalarial chemotherapy. We assessed susceptibilities of fresh Plasmodium falciparum isolates from eastern Uganda to seven proteasome inhibitors: two asparagine ethylenediamines, two macrocyclic peptides, and three peptide boronates; five had median IC values <100 nM. TDI8304, a macrocylic peptide lead compound with drug-like properties, had a median IC of 16 nM.
View Article and Find Full Text PDFMicrobiol Spectr
October 2022
Department of Pathology, Rhode Island Hospital, Providence, Rhode Island, USA.
Rapid identification of pathogens is critical in bloodstream infections. We evaluated the diagnostic performance of the GenMark Dx ePlex blood culture identification (BCID) panels and the adoption of the ePlex system into the clinical laboratory workflow. Nonduplicate remnant specimens of positive blood cultures were prospectively tested using ePlex panels between January and March 2020.
View Article and Find Full Text PDFmSphere
August 2022
Molecular Microbiology and Immunology Department, Brown Universitygrid.40263.33, Providence, Rhode Island, USA.
Candida albicans is a pathobiont fungus that can colonize multiple niches in the human body but is also a frequent cause of both mucosal and systemic disease. Despite its clinical importance, a paucity of dominant selectable markers has hindered the development of tools for genetic manipulation of the species. One factor limiting the utilization of dominant selectable markers is that C.
View Article and Find Full Text PDFMicrobiol Spectr
June 2022
Brown Universitygrid.40263.33, Physics Department, Providence, Rhode Island, USA.
Many species of bacteria change their morphology and behavior under external stresses. In this study, we report transient elongation and swimming motility of a novel Enterobacter sp. strain, SM1_HS2B, in liquid broth under a standard growth condition.
View Article and Find Full Text PDFAntimicrob Agents Chemother
June 2022
Warren Alpert Medical School of Brown Universitygrid.40263.33, Providence, Rhode Island, USA.
Microbiol Spectr
April 2022
Brown Universitygrid.40263.33, Providence, Rhode Island, USA.
HIV-1 drug resistance remains a global challenge, yet access to testing is limited, particularly in resource-limited settings. We examined feasibility and limitations of genotyping using dried filter analytes in treatment-experienced Kenyan youth with HIV. Youth infected with HIV perinatally were enrolled in 2016-2018 at the Academic Model Providing Access to Healthcare in Eldoret, western Kenya.
View Article and Find Full Text PDFmBio
December 2021
Department of Molecular Microbiology and Immunology, Brown Universitygrid.40263.33, Providence, Rhode Island, USA.
Candida albicans is a pathobiont that colonizes multiple niches in the body including the gastrointestinal (GI) tract but is also responsible for both mucosal and systemic infections. Despite its prevalence as a human commensal, the murine GI tract is generally refractory to colonization with the C. albicans reference isolate SC5314.
View Article and Find Full Text PDFAntimicrob Agents Chemother
September 2021
Department of Medicine, University of California, San Franciscogrid.266102.1, California, USA.
Among novel compounds under recent investigation as potential new antimalarial drugs are three independently developed inhibitors of the Plasmodium falciparum P-type ATPase (PfATP4): KAE609 (cipargamin), PA92, and SJ733. We assessed susceptibilities to these compounds of 374 fresh P. falciparum isolates collected in Tororo and Busia districts, Uganda, from 2016 to 2019.
View Article and Find Full Text PDF